Targeting Epidermal Growth Factor Receptor and Src Pathways in Head and Neck Cancer

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 286-297

  Egloff, Ann Marie ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANTISENSE OLIGONUCLEOTIDE; BIBW 2992; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NIMOTUZUMAB; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE; ZALUTUMUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG POTENTIATION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RASH; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 44649115694     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.008     Document Type: Article

References (109)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
2. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
3. Lee J.W., Soung Y.H., Kim S.Y., Nam H.K., Park W.S., Nam S.W., et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 2879-2882
4. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., Hilbe W., Schwentner I., Sprinzl G.M., et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42 (2006) 109-111
5. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (1993) 3579-3584
6. Storkel S., Reichert T., Reiffen K.A., and Wagner W. EGFR and PCNA expression in oral squamous cell carcinomas-a valuable tool in estimating the patient's prognosis. Eur J Cancer 29B (1993) 273-277
7. Lee C.S., Redshaw A., and Boag G. Epidermal growth factor receptor immunoreactivity in human laryngeal squamous cell carcinoma. Pathology 29 (1997) 251-254
8. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
9. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
10. Maurizi M., Scambia G., Benedetti Panici P., Ferrandina G., Almadori G., Paludetti G., et al. EGF receptor expression in primary laryngeal cancer: correlation with clinico-pathological features and prognostic significance. Int J Cancer 52 (1992) 862-866
11. Dassonville O., Formento J.L., Francoual M., Ramaioli A., Santini J., Schneider M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 (1993) 1873-1883
12. Almadori G., Cadoni G., Galli J., Ferrandina G., Scambia G., Exarchakos G., et al. Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer 84 (1999) 188-191
13. Chung C.H., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24 (2006) 4170-4176
14. Temam S., Kawaguchi H., El-Naggar A.K., Jelinek J., Tang H., Liu D.D., et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25 (2007) 2164-2170
15. Singh A.B., and Harris R.C. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17 (2005) 1183-1193
16. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
17. Xia W., Lau Y.K., Zhang H.Z., Liu A.R., Li L., Kiyokawa N., et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3 (1997) 3-9
18. Khan A.J., King B.L., Smith B.D., Smith G.L., DiGiovanna M.P., Carter D., et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8 (2002) 540-548
19. Cavalot A., Martone T., Roggero N., Brondino G., Pagano M., Cortesina G., et al. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29 (2007) 655-664
20. Xia W., Lau Y.K., Zhang H.Z., Xiao F.Y., Johnston D.A., Liu A.R., et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5 (1999) 4164-4174
21. Ekberg T., Nestor M., Engstrom M., Nordgren H., Wester K., Carlsson J., et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26 (2005) 1177-1185
22. Udayachander M., Dean C.J., Meenakshi A.N., Sivakumar N., Babu P.B., and Sivakumar J. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor. Hum Antibodies 8 (1997) 60-64
23. He Y., Zeng Q., Drenning S.D., Melhem M.F., Tweardy D.J., Huang L., et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 90 (1998) 1080-1087
24. Thomas S.M., Zeng Q., Epperly M.W., Gooding W.E., Pastan I., Wang Q.C., et al. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38. Clin Cancer Res 10 (2004) 7079-7087
25. Egloff A.M., and Grandis J. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets 10 (2006) 639-647
26. Specenier P.M., and Vermorken J.B. Targeted therapies in head and neck cancer. Targ Oncol 2 (2007) 73-88
27. FDA Approval for Cetuximab-National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/fda-cetuximab Accessed April 3, 2008
28. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
29. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
30. Vermorken J., Mesia R., Vega V., Remenar E., Hitt R., Kawecki A., et al. Cetuximab extends survival of patients with recurrent or metastatis SCCHN when added to first line platinum based therapy-results of a randomized phase III (Extreme) study [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 25 (2007) 6091
31. Herbst R.S., Arquette M., Shin D.M., Dicke K., Vokes E.E., Azarnia N., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
32. Baselga J., Trigo J.M., Bourhis J., Tortochaux J., Cortes-Funes H., Hitt R., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
33. Vermorken J.B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 (2007) 2171-2177
34. Burtness B.G.M., Flood W., Mattar B., Forastiere A.A., and Group ECO. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
35. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 (2005) 1803-1810
36. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
37. Giusti R.M., Shastri K.A., Cohen M.H., Keegan P., and Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist 12 (2007) 577-583
38. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 12004;73:4699-707.
39. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22 (2004) 1646-1654
40. Kirby A.M., A'Hern R.P., D'Ambrosio C., Tanay M., Syrigos K.N., Rogers S.J., et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94 (2006) 631-636
41. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
42. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., et al. E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
43. FDA Approval for Erlotinib Hydrochloride. http://www.cancer.gov/cancertopics/druginfo/fda-erlotinib-hydrochloride Accessed April 3, 2008
44. Siu L.L., Soulieres D., Chen E.X., Pond G.R., Chin S.F., Francis P., et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25 (2007) 2178-2183
45. FDA Approval for Gefitinib-National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/fda-gefitinib Accessed April 3, 2008
46. Ahmed S.M., Cohen E.E., Haraf D.J., Stenson K.M., Blair E., Brockstein B.E., et al. Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC) [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 25 (2007) 6028
47. Stewart J.S.W., Cohen E.E., Licitra L., Van Herpen C.M.L., Khorprasert C., Soulieres D., et al. A phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck [abstract 3522]. American Association for Cancer Research Annual Meeting: Proceedings (2007), AACR, Los Angeles, CA
48. Niwa H., Wentzel A.L., Li M., Gooding W.E., Lui V.W., and Grandis J.R. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9 (2003) 5028-5035
49. Li M., Ye C., Feng C., Riedel F., Liu X., Zeng Q., et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 8 (2002) 3570-3578
50. FDA Approval for Lapatinib Ditosylate. http://www.cancer.gov/cancertopics/druginfo/fda-lapatinib Accessed April 3, 2008
51. Rusnak D.W., Affleck K., Cockerill S.G., Stubberfield C., Harris R., Page M., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61 (2001) 7196-7203
52. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64 (2004) 6652-6659
53. Abidoye O.O., Cohen E.E., Wong S.J., Kozloff M.F., Nattam S.R., Stenson K.M., et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 24 (2006) 5568
54. Reid A., Vidal L., Shaw H., and de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
55. Morin M.J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19 (2000) 6574-6583
56. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Rel Cancer 11 (2004) 689-708
57. Maa M.C., Leu T.H., McCarley D.J., Schatzman R.C., and Parsons S.J. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci U S A 92 (1995) 6981-6985
58. Tice D.A., Biscardi J.S., Nickles A.L., and Parsons S.J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A 96 (1999) 1415-1420
59. Scaltriti M., and Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12 (2006) 5268-5272
60. Ishizawar R., and Parsons S.J. c-Src and cooperating partners in human cancer. Cancer Cell 6 (2004) 209-214
61. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
62. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
63. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glysogen symthase kinase-3 beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12 (1998) 3499-3511
64. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., and Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14 (2000) 2501-2514
65. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S., and Tweardy D.J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102 (1998) 1385-1392
66. Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97 (2000) 4227-4232
67. Kijima T., Niwa H., Steinman R.A., Drenning S.D., Gooding W.E., Wentzel A.L., et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13 (2002) 355-362
68. Zhang Q., Thomas S.M., Lui V.W., Xi S., Siegfried J.M., Fan H., et al. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 103 (2006) 6901-6906
69. Zhang Q., Thomas S.M., Xi S., Smithgall T.E., Siegfried J.M., Kamens J., et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64 (2004) 6166-6173
70. Ishizawar R.C., Miyake T., and Parsons S.J. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 36 (2007) 3503-3510
71. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Ann Rev Cell Dev Biol 13 (1997) 513-609
72. Irby R.B., Mao W., Coppola D., Kang J., Loubeau J.M., Trudeau W., et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21 (1999) 187-190
73. Daigo Y., Furukawa Y., Kawasoe T., Ishiguro H., Fujita M., Sugai S., et al. Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients. Cancer Res 59 (1999) 4222-4224
74. Nilbert M., and Fernebro E. Lack of activating c-SRC mutations at codon 531 in rectal cancer. Cancer Genet Cytogenet 121 (2000) 94-95
75. Irby R.B., and Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 19 (2000) 5636-5642
76. Summy J.M., and Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metast Rev 22 (2003) 337-358
77. Xi S., Zhang Q., Dyer K.F., Lerner E.C., Smithgall T.E., Gooding W.E., et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278 (2003) 31574-31583
78. Yang Z., Bagheri-Yarmand R., Wang R.A., Adam L., Papadimitrakopoulou V.V., Clayman G.L., et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10 (2004) 658-667
79. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N- (2-chloro-6-methyl- phenyl)-2- (6- (4- (2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 (2004) 6658-6661
80. FDA Approval for Dasatinib-National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/fda-dasatinib Accessed April 3, 2008
81. Johnson F.M., Saigal B., Talpaz M., and Donato N.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11 (2005) 6924-6932
82. Donnini S., Monti M., Castagnini C., Solito R., Botta M.S., Giachetti A., et al. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous cell carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int J Cancer 120 (2007) 995-1004
83. Summy J.M., Trevino J.G., Lesslie D.P., Baker C.H., Shakespeare W.C., Wang Y., et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 4 (2005) 1900-1911
84. Ellis L.M., Staley C.A., Liu W., Fleming R.Y., Parikh N.U., Bucana C.D., et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-Src. J Biol Chem 273 (1998) 1052-1057
85. Resh M.D. Interaction of tyrosine kinase oncoproteins with cellular membranes. Biochim Biophys Acta 1155 (1993) 307-322
86. Sicheri F., and Kuriyan J. Structures of Src-family tyrosine kinases. Curr Opin Struct Biol 7 (1997) 777-785
87. Xu W., Doshi A., Lei M., Eck M.J., and Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3 (1990) 629-638
88. Thomas J.W., Ellis B., Boerner R.J., Knight W.B., White II G.C., and Schaller M.D. SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem 273 (1998) 577-583
89. Alonso G., Koegl M., Mazurenko N., and Courtneidge S.A. Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J Biol Chem 270 (1995) 9840-9848
90. Yagi R., Waguri S., Sumikawa Y., Nada S., Oneyama C., Itami S., et al. C-terminal Src kinase controls development and maintenance of mouse squamous epithelium. EMBO J 26 (2007) 1234-1244
91. Okada M., Nada S., Yamanashi Y., Yamamoto T., and Nakagawa H. CSK: a protein kinase involved in regulation of src family kinases. J Biol Chem 266 (1991) 24249-24252
92. Roskoski Jr. R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331 (2005) 1-14
93. Boyer B., Bourgeois Y., and Poupon M.F. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 21 (2002) 2347-2356
94. Nakagawa T., Tanaka S., Suzuki H., Takayanagi H., Miyazaki T., Nakamura K., et al. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int J Cancer 88 (2000) 384-391
95. Cam W.R., Masaki T., Shiratori Y., Kato N., Ikenoue T., Okamoto M., et al. Reduced C-terminal Src kinase activity is correlated inversely with pp60 (c-src) activity in colorectal carcinoma. Cancer 92 (2001) 61-70
96. Masaki T., Okada M., Tokuda M., Shiratori Y., Hatase O., Shirai M., et al. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 29 (1999) 379-384
97. Bjorge J.D., Pang A., and Fujita D.J. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 275 (2000) 41439-41446
98. Manley P.W., Cowan-Jacob S.W., and Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 1754 (2005) 3-13
99. Haura E.B., Song L., Lee F., Jove R., et al. Effect of dasatinib, a Src kinase inhibitor, on lung cancer cells with defined epidermal growth factor receptor status [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 24 (2006) 3019
100. Koppikar P, Choi SH, Egloff AM, Suzuki S, Freilino M, Cai Q, et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res. In press.
101. Hiscox S., Jordan N.J., Morgan L., Green T.P., and Nicholson R.I. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metast 24 (2007) 157-167
102. Hiscox S., Morgan L., Green T., and Nicholson R.I. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 13 (2006) S53-S59
103. Herynk M.H., Beyer A.R., Cui Y., Weiss H., Anderson E., Green T.P., et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5 (2006) 3023-3031
104. Gautschi O., Purnell P., Evans C.P., Yang J.C., Holland W.S., Bold R.J., et al. Preclinical evaluation of the dual specific Src/Abl kinase inhibitor AZD0530 in lung cancer [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 24 (2006) 13108
105. Lockton J.A., Smethurst D., Macpherson M., Tootell R., Marshall A.L., Clack G., et al. Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 23 (2005) 3125
106. Tabernero J., Cervanter A., Hoekman K., Hurwitz H.I., Jodrell D.I., Hamberg P., et al. Phase I study of AZD00530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J Clin Oncol Proc Am Soc Clin Oncol 25 (2007) 3520
107. Johnson F.M., Chiappori A., Burris H., Rosen L., McCann B., Luo F.R., et al. A phase I study (CA180021-Segment 2) of dasatinib in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol Proc Am Soc Clin Oncol 25 (2007) 14042
108. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 20051-12
109. Kopetz S., Wu J., Davies M., Johnson F., and Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer [abstract 406]. Am Soc Clin Oncol Gastrointestinal Cancers Symposium. Orlando, FL, January 19-21 (2007)